A cross-sectional study on the concordance between vaginal HPV DNA detection and type-specific antibodies in a multi-ethnic cohort of women from Amsterdam, the Netherlands – the HELIUS study

Table 2 Vaginal hrHPV DNA and type-specific seropositivity^a, and association of vaginal hrHPV DNA with type-specific antibodies^b

HPV type^c	HPV DNA detected n (%)	HPV seropositive n (%)	Seropositive among DNA + n (%)^d	Seropositive among DNA - n (%)^e	Crude OR for seropositivity (95 % CI)^f
16	32 (6 %)	73 (14 %)	6 (19 %)	67 (13 %)	1.49 (0.59,3.76)
18	20 (4 %)	59 (11 %)	4 (20 %)	55 (11 %)	2.08 (0.67,6.44)
31	28 (5 %)	68 (13 %)	6 (21 %)	62 (12 %)	1.94 (0.76,4.98)
33	7 (1 %)	36 (7 %)	2 (29 %)	34 (6 %)	5.78 (1.08,30.88)
45	8 (2 %)	51 (10 %)	1 (13 %)	50 (10 %)	1.35 (0.16,11.23)
52	43 (8 %)	54 (10 %)	9 (21 %)	45 (9 %)	2.61 (1.18,5.97)
58	9 (2 %)	46 (9 %)	3 (33 %)	43 (8 %)	5.58 (1.35,23.10)

CI, confidence interval; hrHPV, high risk human papillomavirus; IQR, interquartile range; OR, odds ratio. ^a Among 532 women from a population-based cohort (HELIUS), Amsterdam, the Netherlands. ^bUnivariable analysis conducted with logistic regression. ^c Cut-offs used in this study: 422 MFI for HPV-16, 394 for HPV-18, 712 for HPV-31, 515 for HPV-33, 368 for HPV-45, 547 for HPV-52, and 371 MFI for HPV-58. ^dAmong number of HPV DNA positive women in column 2. ^eAmong number of HPV DNA negative women, i.e. the number cited in column 2 subtracted from 532. ^fMultivariable analysis was not undertaken because of small numbers

ISSN: 1471-2334